文献速递神经核医学肿瘤 PET/CT

18F-FDG PET在局灶性皮质发育不良2型所致药物难治性癫痫中的价值:电临床数据与MRI融合的附加作用

18F-FDG PET in drug-resistant epilepsy due to focal cortical dysplasia type 2: additional value of electroclinical data and coregistration with MRI.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-03-29

该研究分析了103例经组织学证实为局灶性皮质发育不良2型(FCD2)的药物难治性癫痫患者的18F-FDG PET。视觉分析仅44%患者PET与FCD2一致,结合电临床数据后阳性定位增至73例,PET/MRI融合后增至85例(83%);MRI阳性61例(59%)。结论认为PET结合电临床与融合技术对FCD2定位贡献达83%,可能有助于改善手术结局。

要点

  • 视觉分析PET仅44%患者与FCD2一致,结合电临床和PET/MRI融合后定位阳性达83%。
  • MRI阴性或可疑患者中PET额外定位价值显著,83%可定位FCD2。
  • 误导性定位与额叶内侧和中央区小FCD2相关;术后94%无发作。

核心结论

  • 在本系列中,18F-FDG PET通过整合电临床数据和PET/MRI融合,对83%的患者实现了FCD2定位。
  • 该方法可能有助于改善颞外癫痫的手术结局,即使MRI阴性患者亦然。

研究设计与样本

  • 回顾性分析103例连续患者(52例男性,7-65岁)经组织学证实为FCD2的18F-FDG PET扫描。
  • PET和MRI数据先在不告知临床信息和FCD2位置的条件下进行视觉分析。
  • 通过对比病理结果和手术结局评估电临床数据及PET/MRI融合的附加价值。

主要发现

  • 视觉分析PET显示45例(44%)患者局灶或区域代谢减低与FCD2对应,37例可疑或误导,21例阴性。
  • 结合电临床数据后73例获得阳性定位,PET/MRI融合后增至85例(83%)。
  • 相同条件下MRI阳性61例(59%),可疑15例,阴性27例。
  • MRI阴性或可疑患者中PET附加价值显著,35例(83%)可定位FCD2。
  • 观察者间一致性随代谢减低程度变化:轻至重度代谢减低者82-95%良好,细微/可疑代谢减低者45%中等。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the localizing value of 18F-FDG PET in patients operated on for drug-resistant epilepsy due to focal cortical dysplasia type 2 (FCD2). METHODS: We analysed 18F-FDG PET scans from 103 consecutive patients (52 males, 7-65 years old) with histologically proven FCD2. PET and MRI data were first reviewed by visual analysis blinded to clinical information and FCD2 location. The additional value of electroclinical data and PET/MRI coregistration was assessed by comparison with pathological results and surgical outcomes. RESULTS: Visual analysis of PET scans showed focal or regional hypometabolism corresponding to the FCD2 in 45 patients (44%), but the findings were doubtful or misleading in 37 patients and negative in 21. When considering electroclinical data, positive localization was obtained in 73 patients, and this increased to 85 (83%) after coregistration of PET and MRI data. Under the same conditions, MRI was positive in 61 patients (59%), doubtful in 15 and negative in 27. The additional value of PET was predominant in patients negative or doubtful on MRI, localizing the FCD2 in 35 patients (83%). Interobserver agreement correlated with the grade of hypometabolism: it was good in patients with mild to severe hypometabolism (82-95%), but moderate in those with subtle/doubtful hypometabolism (45%). The main factors influencing positive PET localization were the grade of hypometabolism and the size of the FCD2 (P < 0.0001). Misleading location (nine patients) was associated with a small FCD2 in the mesial frontal and central regions. Following limited cortical resection mainly located in extratemporal areas (mean follow-up 5.6 years), a seizure-free outcome was achieved in 94% of patients, including Engel's class IA in 72%. CONCLUSION: In this series, 18F-FDG PET contributed to the localization of FCD2 in 83% of patients. This high localizing value was obtained by integration of electroclinical data and PET/MRI coregistration. This approach may help improve the surgical outcome in extratemporal epilepsy, even in patients negative on MRI.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Desarnaud S, Mellerio C, Semah F, et al. 18F-FDG PET in drug-resistant epilepsy due to focal cortical dysplasia type 2: additional value of electroclinical data and coregistration with MRI. Eur J Nucl Med Mol Imaging. 2018. PMID: 29594410. doi:10.1007/s00259-018-3994-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。